MedTrace Logo

Real World Data Study Assessing The Persistency Of Xalacom And The Other Fixed Dose Combination Products, Duotrav And Ganfort, In The United Kingdom

NCT01206361 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2015

Last updated 2021-02-02

No results posted yet for this study

Summary

The hypothesis is that there is no difference in persistency between Xalacom and the alternative fixed dose combination products (Duotrav and Ganfort) over a 12 month period.

Conditions

Interventions

DRUG

XALACOM

Xalacom eye drops

DRUG

Duotrav

Duotrav eye drops

DRUG

Ganfort

Ganfort eye drops

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2010-08-31
Completion
2010-08-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01206361 on ClinicalTrials.gov